Elevated viral transcription factor levels in cortical blood vessels in schizophrenia by Siegel, Benjamin
 1 
 
Elevated Viral Transcription Factor Levels in Cortical Blood Vessels in Schizophrenia 
 
 
 
 
 
 
 
by 
Benjamin I. Siegel 
Bachelor of Science, University of Pittsburgh, 2013 
 
 
 
 
 
 
 
 
 
 
Submitted to the Graduate Faculty of the 
University Honors College in partial fulfillment  
of the requirements for the degree of 
Bachelor of Philosophy 
 
 
 
 
 
 
 
 
 
University of Pittsburgh 
2013 
 
 2 
UNIVERSITY OF PITTSBURGH 
University Honors College 
 
 
 
 
 
 
 
 
This thesis was presented 
 
by 
 
 
Benjamin I. Siegel 
 
 
 
It was defended on 
April 8, 2013 
and approved by 
Karoly Mirnics, MD, PhD, Department of Psychiatry, Vanderbilt University 
David Lewis, MD, Department of Psychiatry, University of Pittsburgh 
Etienne Sibille, PhD, Department of Psychiatry, University of Pittsburgh 
 Thesis Advisor and Committee Chair: David Volk, MD, PhD, Department of Psychiatry, 
University of Pittsburgh 
 
 
 3 
  
Copyright © by Benjamin I. Siegel 
2013 
Elevated Viral Transcription Factor Levels in Cortical Blood Vessels in Schizophrenia 
Benjamin I Siegel, BPhil 
University of Pittsburgh, 2013
 
 4 
Context and Rationale: Schizophrenia is a pervasive and devastating mental disorder, but the 
current available treatments do not alleviate the most debilitating feature of the disease: the 
cognitive deficits, specifically impairments in working memory. Through a translational 
approach, which involves tracing the disorder from its etiologic components to its clinical 
manifestations, novel and effective treatment strategies can be developed. Although the etiology 
of schizophrenia is extremely complex, a predominant risk factor is immune overactivation early 
in life, especially in-utero, that persists into adulthood. Additionally, the core pathologic source 
of the working memory impairments can be traced to dysfunctional GABA circuitry in the 
dorsolateral prefrontal cortex (DLPFC).  In a previous study using a relatively small sample of 
schizophrenia subjects, mRNA levels of IFITM, a broad-spectrum viral restriction factor, has 
been shown to be markedly elevated in the DLPFC. This localized elevation, when considered 
with IFITM’s role as marker of immune activity, suggests that IFITM may be related to both the 
GABA circuitry deficiency and the residual immune dysfunction characteristic of schizophrenia. 
 
Study Objectives: To further evaluate IFITM’s status in the DLPFC in schizophrenia, the 
present study had four aims: (1) replicate the finding of higher levels of IFITM mRNA in the 
prefrontal cortex in a larger cohort of schizophrenia subjects; (2) evaluate whether the IFITM 
elevation in schizophrenia is attributable to factors that are associated with, but not central to, the 
disorder; (3) determine the cell types that overexpress IFITM mRNA in schizophrenia; and (4) 
investigate whether higher IFITM mRNA levels are correlated with abnormal GABA-related 
marker mRNAs in the same schizophrenia subjects. 
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Methods: We used quantitative PCR (qPCR) and in situ hybridization (ISH) with film and grain 
counting analyses to quantify IFITM mRNA levels in postmortem samples of prefrontal cortex 
area 9 of 57 schizophrenia subjects and 57 comparison subjects. We then compared the findings 
to previously reported mRNA expressions of GABA-related markers in the same cohort of 
schizophrenia subjects. Transcript levels for IFITM mRNA were also assessed by qPCR in the 
prefrontal cortex of monkeys chronically exposed to antipsychotic medications. 
 
Results: In schizophrenia subjects, IFITM mRNA levels were markedly higher in both qPCR 
and ISH analyses. The finding could not be attributed to infection- or inflammation-related cause 
of death, psychotropic medication use at time of death, or nicotine use at time of death. IFITM 
mRNA levels were not altered in the prefrontal cortex of antipsychotic-exposed monkeys. ISH 
analyses revealed that IFITM mRNA levels were predominantly elevated in cortical blood 
vessels in schizophrenia. Furthermore, higher IFITM mRNA levels measured by qPCR are 
associated with deficits in prefrontal GABA markers in schizophrenia.  
 
Conclusions: The localization of IFITM to blood vessels in the prefrontal cortex suggests that 
the viral restriction factor is involved in immunoprotection provided by the blood-brain barrier, 
which has also been shown to be disrupted in schizophrenia. Considering that indicators of 
neuroinflammation are a pervasive finding in schizophrenia and that alterations in both GABA-
related markers and IFITM have been associated with inflammatory processes, the correlation 
between IFITM mRNA overexpression in blood vessels and deficits in GABA-related markers 
may be explained by an common upstream insult, such as maternal immune activation mediated 
by inflammatory cytokine elevation or chronic neuroinflammation. 
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1.0  INTRODUCTION 
Schizophrenia is a devastating mental disorder that affects approximately 1% of the global 
population (McGrath et al. 2008). The disease leads to debilitating deficits in interpersonal and 
intellectual abilities that often prevent its sufferers from maintaining relationships with friends 
and family. Possibly because of the destructive effects that the disorder has on one’s ability to 
function, 20% of individuals with schizophrenia are homeless (Folsom et al. 2005). Onset of the 
disorder typically occurs during late adolescence or early adulthood, and suicide is disturbingly 
common –it is estimated that between 5% (Palmer et al. 2005) and 10% (Tsuang 1978) of 
individuals with schizophrenia ultimately take their own lives. Indeed, suicide is one of the 
leading causes of death for schizophrenia. 
While it is a tremendously complex disorder, schizophrenia can be broken down into 
three broad categories of symptoms: positive, negative, and cognitive. The positive symptoms 
are marked by additions to a person’s behavior and experience and include delusions, fixed, 
false, internally validated beliefs that have little or no basis in reality and cannot be eradicated by 
appeals to logic; visual or (more commonly) auditory hallucinations, in which the individual 
perceives objects or voices that are not actually present; and thought disorders, which render the 
patient unable to think clearly enough to produce coherent speech. Conversely, the negative 
symptoms are named as such because they are the absence of parts of a person’s behavior and 
experience. For example, social withdrawal, lack of personal hygiene, and amotivation are all 
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considered negative symptoms. The cognitive deficits include deficiencies in general processing 
speed and problem solving, impairments in the processing of social information, inability to 
select and maintain appropriate attentional foci, as well as difficulty with verbal and visual 
learning (Green 2006). Of particular note are the deficits in working memory, which normally 
allows individuals to use temporary information related to a stimulus (like a phone number in a 
phonebook) to guide behavior (like dialing the number) before it is forgotten.  
All of the medications currently available to treat schizophrenia act primarily by 
attenuating the positive symptoms of the disease. Despite this predominance of positive 
symptom-oriented therapy in the treatment of schizophrenia, it has been well documented that 
there is only a minimal relationship between psychotic symptoms and either social or 
occupational functioning (Green 1996).  Instead, these outcome measures have been shown to be 
strongly associated with cognitive deficits Indeed, deficits in cognition have been shown to be 
the best predictors of long-term outcome for individuals with schizophrenia (Elvevåg and 
Goldberg 2000). Consequently, in order to develop more effective treatments and preventative 
strategies for the disorder, one must first understand the underlying processes, such as genetic 
and environmental risk factors as well as developmental phenomena, that culminate in the 
debilitating cognitive deficits characteristic of the disorder.  
1.1 TRANSLATIONAL APPROACH TO SCHIZOPHRENIA 
In the April 2005 issue of Nature Reviews Neuroscience, Lewis et al presented a framework 
through which these processes may be elucidated (Figure 1)(Lewis et al. 2005). This framework 
is structured around the assumption that the clinical phenotype known as schizophrenia can 
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ultimately be traced back to some combination of genetic abnormalities and environmental 
insults, which initiate a series of pathological phenomena that eventually result in the clinical 
phenotype. These genetic and environmental causes comprise the etiology of the disorder, and 
lead to pathogenic changes in normal brain mechanisms. The disease mechanisms result in 
anatomic or molecular alterations (pathological entity), which upset normal brain functioning 
(pathophysiology). In turn, the abnormal brain function produces the clinical syndrome 
characteristic of the disorder. Importantly, there are two intervention points (prevention and 
treatment) along this cascade that provide an opportunity to eliminate, or at least attenuate, the 
clinical syndrome. That is, by preventing the pathogenic mechanisms from altering brain 
structure or by treating the pathophysiologic activity directly, the disease symptoms can be 
effectively mitigated. 
 
 
 
 
 
Figure 1. Translational neuroscience approach to disease 
(modified from (Lewis et al. 2005)) 
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1.1.1 Pathophysiology  
Impairments in working memory are commonly reported in schizophrenia (Lee and Park 2005; 
Forbes et al. 2009) and have been implicated as a core neurocognitive feature (Goldman-Rakic 
1994) of the disorder. Working memory is subserved by the circuitry of the dorsolateral 
prefrontal cortex (DLPFC) (Petrides 2000), so one would expect there to be abnormal 
functioning of the DLPFC in schizophrenia during working memory tasks.  Indeed, functional 
neuroimaging studies have demonstrated profound alterations in DLPFC activity during working 
memory tasks (Minzenberg et al. 2009). For example, studies examining fMRI data during the 
N-back working memory task have shown that individuals with schizophrenia have a limited 
working memory capacity and abnormal DLPFC functioning (Callicott et al. 2003;Callicott et al. 
2000). Rather than being consistently hypo- or hyperfrontal, these abnormalities were 
characterized by differences in activity that varied by location within the region, suggesting poor 
modulation of neural activity in response to a changing cognitive load. That is, the working 
memory deficits seen in the disorder may be due in part to dysfunctional information handling 
and processing within the DLPFC. 
 The abnormal neural activity suggested by fMRI studies can be investigated by 
examining the EEGs of patients with schizophrenia during working memory tasks. Indeed, a 
strong body of research has shown that DLPFC neural firing patterns in the gamma frequency 
range (30-80 Hz), which are known to be associated with top-down processes such as working 
memory (Howard et al. 2003), are abnormal in schizophrenia (Minzenberg et al. 2010;Cho et al. 
2006).In normal individuals, the amplitude (or power) of gamma band oscillations is positively 
correlated with working memory load (Howard et al. 2003).  However, this increase in prefrontal 
gamma power is diminished in schizophrenia (Minzenberg et al. 2010;Cho et al. 2006). Gamma 
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oscillations have been shown to be associated with fMRI signal change (Logothetis et al. 
2001;Mukamel et al. 2005), so it is likely that the impaired modulation of gamma activity seen in 
EEG studies is involved in the formation of the deficits found in neuroimaging studies. 
Therefore, given that the gamma power deficits are correlated with symptom severity (Cho et al. 
2006), they may represent a pathophysiologic mechanism through which the working memory 
deficits emerge.  
 
1.1.2 Pathological Entity  
The origin of prefrontal gamma oscillations is not fully understood, but it is likely that they 
emerge from rhythmic firing of GABA-releasing inhibitory interneurons onto pyramidal cells, 
which are the major excitatory neurons in the cortex. The rhythmic inhibition results in the 
synchronous firing of millions of pyramidal cells in gamma frequency range. If prefrontal GABA 
neurotransmission is reduced, then gamma oscillations become disrupted (Lodge et al. 2009) and 
cognitive function is impaired (Enomoto et al. 2011;Gruber et al. 2010;Paine et al. 
2011;Sawaguchi et al. 1989). It has been shown that interneurons expressing parvalbumin (PV), 
a calcium-binding protein, play a particularly important role in this process. Specifically, 
inhibition of PV interneurons has been shown to suppress gamma oscillations in mice, while 
stimulation increases gamma oscillations (Sohal et al. 2009).  
In schizophrenia, there are severe alterations in both PV interneurons and GABA 
neurotransmission in general. For example, a number of studies examining post-mortem human 
DLPFC tissue have found reductions in mRNA levels of GAD67, a GABA synthesizing enzyme, 
in schizophrenia (Akbarian et al. 1995;Volk et al. 2000). In PV interneurons specifically, the 
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GAD67 deficits appear to be especially severe – in one study, 50% of PV interneurons were found 
to contain undetectable levels of GAD67 mRNA in the schizophrenia subjects (Hashimoto et al. 
2003). Without adequate levels of the GABA synthesizing enzyme, PV interneurons are unable 
to adequately inhibit their pyramidal cell targets, which may prevent the synchronous firing 
required to create gamma oscillations. Further support for this explanation comes from the 
finding that mRNA levels of the α1 subunit of the GABA receptor, which is the postsynaptic 
target for PV interneurons onto pyramidal cells, have been shown to be reduced in schizophrenia 
(Glausier and Lewis 2011).Taken together, these findings suggest that dysfunctional GABA-
mediated inhibitory circuitry in the DLPFC, especially as it relates to PV interneurons, is one of 
the pathological entities that results in a pathophysiological reduction in gamma oscillations, 
which then contributes to the clinical syndrome of working memory dysfunction. Figure 2 
superimposes these conclusions onto the Lewis et al framework. 
 
 
 
 
 
Figure 2. Translational neuroscience approach to schizophrenia 
(modified from (Lewis et al. 2005)) 
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1.1.3 Uncovering Etiology  
While little is known about the pathogenetic processes that produce GABA circuitry dysfunction 
in schizophrenia, a number of converging lines of research have shed light on the disorder’s 
etiology. Most importantly, it is clear that schizophrenia emerges from both genetic and 
environmental factors. Indeed, the heritability for the disorder is approximately 0.81, meaning 
that about 81% of the variability between individuals in the disorder is due to genetic factors 
(Sullivan et al. 2003).Identifying the specific genes responsible for the disorder is tremendously 
complicated; however, evidence suggests that the disorder is polygenic, potentially involving 
thousands of SNPs (Purcell et al. 2009). 
Regardless of the precise nature of the genetic risk factors, schizophrenia appears to fit a 
diathesis-stress model, in which individuals possess a certain degree of genetic predisposition 
that makes them more vulnerable to developing the disease when exposed to certain 
environmental stressors. Indeed, while genetics play a crucial role in the disease, it has been 
shown that the concordance rate for identical twins is only about 50%, implying that 
environmental factors heavily influence whether an individual actually develops the disorder 
(Tsuang 2000). Importantly, many of these environmental stressors tend to occur during periods 
of high neurodevelopmental activity. For example, heavy cannabis use during adolescence and 
childhood trauma are both associated with higher risk for developing schizophrenia. 
Furthermore, individuals with schizophrenia are more likely to have suffered from pre- or 
perinatal complications, such as fetal hypoxia and prenatal exposure to infection or toxins 
(Brown 2011). 
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1.2 NEURODEVELOPMENT AND IMMUNE DYSFUNCTION 
The timing of these environmental risk factors suggests that there is a core neurodevelopmental 
component to schizophrenia. Indeed, the cognitive deficits that become so pronounced later in 
the illness are actually present in a less severe form in individuals prior to the onset of the 
disease. In addition, the cognitive problems worsen as the individual traverses adolescence into 
adulthood, even if schizophrenia onset does not occur until later in life (Reichenberg et al. 2010).  
These findings suggest that in individuals who ultimately develop the disorder, there is an offset 
in normal neurodevelopment that prevents proper brain maturation, possibly resulting in the 
dysfunctional prefrontal inhibitory circuitry characteristic of the disorder. 
Interestingly, developmental delays have even been reported before age one in 
individuals who will eventually development schizophrenia (Sorensen et al. 2010), suggesting 
that the neurodevelopmental trajectory may begin to go off track very early in life. Given that 
Brown et al estimated that up to 30% of schizophrenia cases may be attributable to maternal 
infection (Brown and Derkits 2010), prenatal exposure to infection may represent an 
environmental insult that may be involved in this neurodevelopmental offset. Indeed, in one 
study 20% of fetuses who were exposed to the rubella virus during the first trimester of 
pregnancy went on to develop schizophrenia (Brown et al. 2001), although it should be noted 
that later studies have shown that the type and timing of infection in-utero are not the critical 
factors that affect schizophrenia risk (Brown and Derkits 2010). 
One potential explanation for the association between maternal infection and 
schizophrenia is that, when the mother becomes infected with a pathogen, the fetal brain 
experiences an elevation in cytokines (Meyer et al. 2006). Because PV interneurons express 
cytokine receptors (Wang et al. 2011;Sanchez-Alcaniz et al. 2011;Meechan et al. 2012), perhaps 
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altered fetal cytokine levels in response to maternal immune activation (MIA) could disrupt 
normal neuronal migration of PV neurons, and therefore play a role in the inhibitory circuit 
abnormalities discussed above.  
1.3 IFITM IN SCHIZOPHRENIA 
Because it is impossible to directly look at the brains of schizophrenia patients in-utero, which 
would be the ideal way to investigate the role of maternal immune activation in the disease’s 
etiopathogenesis, more indirect (but converging) approaches must be employed. For example, 
studying adults with schizophrenia can provide indications of insults that happened much earlier 
in life. Indeed, altered serum cytokines is a well-documented finding in adults with 
schizophrenia (Erbagci et al. 2001;Di Nicola et al. 2012;Drzyzga et al. 2006), and one 
postmortem study found elevated mRNA levels of cytokines in the DLPFC of individuals with 
the disorder (Fillman et al. 2012). Given that maternal immune activation has been shown to 
elevate levels of cytokines in the fetal brain (Meyer et al. 2006;Oskvig et al. 2012), and that 
maternal immune activation is relatively common in schizophrenia (Brown and Derkits 2010), 
these findings suggest there may be a residual immune activation that begins in-utero and 
persists into adulthood. Consistent with this interpretation, a microarray study of DLPFC tissue 
in a relatively small number of schizophrenia subjects found elevations in mRNA levels of 
interferon-induced transmembrane protein (IFITM) (Arion et al. 2007), which is a viral 
restriction factor that impedes viral entry into cells and inhibits viral replication (Diamond and 
Farzan 2013). IFITM has been shown to be involved in cellular resistance to a wide range of 
viruses (including influenza, West Nile, dengue, and HIV) (Brass et al. 2009;Huang et al. 
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2011;Lu et al. 2011), so it likely plays an important role in broad-spectrum antiviral activity 
(Diamond and Farzan 2013). The expression of IFITM mRNA in schizophrenia subjects in the 
Arion et al study was remarkably high – almost an 80% difference between schizophrenia and 
controls. Such an elevation is rare in postmortem studies of schizophrenia, so considering its 
potential involvement in an immune-related pathogenic mechanism, it warrants further 
investigation.  
The marked elevation of IFITM mRNA levels in the DLPFC of schizophrenia raises 
several important questions which are addressed in the present study. First, how common is 
higher IFITM mRNA expression in schizophrenia? Second, is higher IFITM mRNA expression 
an integral part of the disease process, or is it either a consequence of disease-related factors, 
such as antipsychotics and smoking, or a confound of immune/inflammation-related cause of 
death? Third, as little is known about IFITM function in the brain, which cell types normally 
express IFITM and do these cells express higher IFITM mRNA levels in schizophrenia? Fourth, 
is there a relationship between elevated IFITM mRNA levels and deficits in GABA neuron-
related markers in the disorder? Addressing these questions will allow for further investigation 
into IFITM as a potential player in the pathogenesis of schizophrenia. 
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2.0  METHODS 
From these questions, we derived four study aims: 
1. Replicate the finding of higher levels of IFITM mRNA in the prefrontal cortex 
in a larger, new cohort of schizophrenia subjects. 
2. Evaluate whether elevated IFITM mRNA levels in schizophrenia is related to 
disease severity or attributable to factors such as antipsychotic use, smoking 
or late-life immune events. 
3. Determine the cell-types that overexpress IFITM mRNA in schizophrenia.  
4. Investigate whether higher IFITM mRNA levels are related to abnormalities 
in expression of GABA-related markers in the same schizophrenia subjects. 
  
 To address each of these aims, we used postmortem brain tissue of adult individuals with 
and without schizophrenia. Specifically, we studied IFITM mRNA expression in area 9 of the 
PFC using two methods: quantitative PCR (qPCR) and in situ hybridization. qPCR was 
employed to determine the differential mRNA expression of IFITM in DLPFC gray matter 
homogenates of schizophrenia subjects and unafflicted controls. In situ hybridization was used to 
confirm the qPCR findings and to determine which cells in the DLPFC express higher levels of 
IFITM mRNA in schizophrenia. We also used qPCR to quantify IFITM mRNA levels in the 
prefrontal cortex of antipsychotic-exposed monkeys.  
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2.1 HUMAN SUBJECTS 
With consent from next-of-kin, the brain specimens for the study were obtained during routine 
autopsies conducted at the Allegheny County Medical Examiner’s Office. For each 
schizophrenia subject, an independent committee of experienced research clinicians made 
consensus DSMIV (American Psychiatric Association 1994) diagnoses using structured 
interviews with family members and review of medical records (Volk et al. 2010).For the healthy 
comparison subjects, the absence of a psychiatric diagnosis was confirmed in a similar manner. 
To control for experimental variance, subjects with schizophrenia or schizoaffective disorder 
(n=57) were matched individually to one healthy comparison subject for sex and as closely as 
possible for age, as previously described (Volk et al. 2010;Volk et al. 2011;Curley et al. 2011), 
and samples from subjects in a pair were processed together throughout all stages of the study. 
Of the fifty-seven subject pairs, fourteen had previously been studied for IFITM mRNA levels 
by microarray in the Arion et al study (Arion et al. 2007).  As shown in Table 1, the mean age, 
postmortem interval, freezer storage time, brain pH, and RNA integrity number (RIN; Agilent 
Bioanalyzer) did not differ between subject groups. Additionally, each subject had a RIN ≥ 7.0. 
All procedures for the study were approved by the University of Pittsburgh’s Committee for the 
Oversight of Research Involving the Dead and Institutional Review Board.  
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Table 1. Control and Schizophrenia Subject Characteristics 
 Controls Schizophrenia 
 Number Percent Number Percent 
Gender 15F / 42M 26.3F / 73.7M 15F / 42M 26.3F / 73.7M 
Race 47W / 10B 82.5W / 17.5B 43W / 14B 75.4W / 24.6B 
 Mean SD Mean SD 
Age (years) 48.1 13.9 46.9 12.9 
PMIa 18.2 5.4 18.9 8.5 
ST qPCRb 113 50 109 54 
ST ISHb 92 34 81 25 
RINc 8.2 0.6 8.1 0.6 
Brain pH 6.7 0.3 6.6 0.3 
a PMI, postmortem interval (hours); b ST, storage time (months) at -80C; c RIN, RNA integrity 
number; F, female; M, male; W, white; B, black 
 
2.2 TISSUE PREPARATION 
Frozen tissue blocks containing the middle portion of the right superior frontal sulcus were 
confirmed to contain prefrontal cortical area 9 using Nissl-stained, cryostat tissue sections for 
each subject (Volk et al. 2000). The gray-white matter boundary of prefrontal area 9 in the tissue 
block from each subject was carefully scored with a scalpel blade where the gray matter had 
uniform thickness and the gray-white matter boundary was easily delineated. The scored gray 
matter region of the tissue block was then digitally photographed, and the number of tissue 
sections (40 µm) required to collect ~30 mm3 of gray matter was determined for each subject. 
The calculated number of required tissue sections for each subject was then cut by cryostat, and 
gray matter was separately collected into a tube containing TRIzol reagent in a manner that 
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ensured minimal white matter contamination and excellent RNA preservation(Hashimoto et al. 
2008). 
2.3 QUANTITATIVE PCR 
2.3.1 Overview 
As indicated above, qPCR can be used to quantify mRNA levels for whole-tissue homogenates. 
In general terms, qPCR is carried out in the following procedure. First, for each subject, RNA is 
isolated from homogenized gray matter via a series of purification reactions. cDNA is then 
synthesized from the tissue mRNA via a reverse transcriptase. Using primers specific for the 
target cDNA sequence, which corresponds to IFITM in this study, the target cDNA sequence is 
then amplified exponentially. As the cDNA is amplified, a fluorescent binding agent (SYBR 
Green) intercalates to the amplified, double stranded cDNA. The fluorescence of the sample can 
then be measured. In this study, the relative mRNA amount in a sample is determined by the 
number of PCR cycles it takes for the fluorescence to reach a standardized detection threshold 
relative to three normalizer genes. Figure 3 shows this process pictorially.  
 
 25 
 
2.3.2 Specific Procedure 
cDNA was synthesized via standardized dilutions of total RNA (10 ng/µl) for each subject using 
the standardized amounts of cortical gray matter. There are three relevant variants of IFITM 
mRNA (IFITM1, IFITM2, IFITM3; IFITM4 is a pseudogene and IFITM5 is only found in 
osteoblasts (Diamond and Farzan 2013). One primer set was designed to quantify IFITM1 
mRNA by targeting a unique region not found in the two other reported IFITM variants in 
humans (IFITM2 and IFITM3). However, due to the very high sequence homology between 
IFITM2 and IFITM3 in humans, a second primer set was designed to quantify IFITM2 and 
IFITM3 mRNAs by targeting a region that is identical between IFITM2 and IFITM3 (termed 
IFITM2/3; Table 2). All primer pairs demonstrated high amplification efficiency (>96%) across 
a wide range of cDNA dilutions and specific single products in dissociation curve analysis. 
 
 
 
Figure 3. qPCR Overview 
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Table 2. qPCR Primer Design 
Gene Species Accession # Amplicon Size (bp) Position 
Forward Primer (F) 
Reverse Primer (R) 
Interferon-induced 
transmembrane 
protein 1 (IFITM1) 
H† NM_003641 82 576-657 (F)  CAACCTTTGCACTCCACTGT (R) GTATCTAGGGGCAGGACCAA 
IFITM2/3* H 
NM_006435 
(IFITM2) 
NM_021034 
(IFITM3) 
59 
441-499 
(IFITM2) 
459-517 
(IFITM3) 
(F) CTGCTCATCATCATCCCAGT 
(R) TGATGCCTCCTGATCTATC 
Beta actin H NM_001101 101 1146-1246 (F)  GATGTGGATCAGCAAGCA (R) AGAAAGGGTGTAACGCAACTA 
Cyclophilin H NM_021130 126 159-284 (F)  GCAGACAAGGTCCCAAAG (R)  GAAGTCACCACCCTGACAAC 
Glyceraldehyde-3-
phosphate 
dehydrogenase 
(GAPDH) 
H NM_002046 87 556-642 (F)  TGCACCACCAACTGCTTAGC (R)  GGCATGGACTGTGGTCATGAG 
IFITM1/3# M† 
XM_001085444 
(IFITM1) 
XM_001106166 
(IFITM3) 
106 323-428 (F)  AGTCCAGGGACAGGAAGATG (R)  GTCATGAGGATGCCCAAAAT 
Beta actin M NM_001033084 101 1087-1187 (F) GATGTGGATCAGCAAGCA (R)AGAAAGGGTGTAACGCAACTA 
Cyclophilin M NM_001032809 126 76-201 (F) GCAGACAAGGTTCCAAAG  (R) GAAGTCACCACCCTGACAC 
GAPDH M XM_001105471 93 527-619 (F) TGCACCACCAACTGCTTAGC (R) AGTGATGGCGTGGACTGTG 
* Due to the very high sequence homology between IFITM2 and IFITM3 in humans, this primer set was designed to 
target an mRNA region that is identical between IFITM2 and IFITM3 (termed IFITM2/3). 
 
# This primer set was designed to target an mRNA region that is identical between all known IFITM variants in 
monkeys, IFITM1 and IFITM3 (termed IFITM1/3). No IFITM2 mRNA sequence for monkeys was available in the 
NCBI data base at the time of primer design. 
 
† Abbreviations: H, human; M, Macaca mulatta 
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Quantitative PCR was performed using the comparative cycle threshold (CT) method 
with Power SYBR Green dye and the StepOnePlus Real-Time PCR System (Applied 
Biosystems). cDNA samples from both subjects in the same pair were processed together on a 
single quantitative PCR plate, and a different plate was utilized for each of the 57 subject pairs. 
Four replicate measures were performed for each transcript for each subject with a detection 
threshold for each gene applied consistently for all subjects. The mean coefficient of variance 
(±SD) of the replicate measures were IFITM1 0.036 (±0.018) and IFITM2/3 0.038 (±0.026). 
Control studies in which the cDNA template was not included in the qPCR reaction resulted in a 
complete lack of amplification. Based on their stable relative expression level between 
schizophrenia and comparison subjects (Hashimoto et al. 2008), three reference genes (beta 
actin, cyclophilin A, and glyceraldehyde-3-phosphate dehydrogenase [GAPDH]) were used to 
normalize target mRNA levels. The difference in CT (dCT) for each target transcript was 
calculated by subtracting the geometric mean CT for the three reference genes from the CT of 
the target transcript (mean of four replicate measures). Because dCT represents the log2-
transformed expression ratio of each target transcript to the reference genes, the relative level of 
the target transcript for each subject is reported as 2-dCT (Vandesompele et al. 2002;Hashimoto et 
al. 2008;Volk et al. 2010;Volk et al. 2011). 
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2.4 IN SITU HYBRIDIZATION 
2.4.1 Overview 
In situ hybridization (ISH) is used in this study to determine which cells in the DLPFC express 
the highest levels of IFITM mRNA, and to evaluate whether the elevation seen in the overall 
tissue (via qPCR) is also present in these cells. The ISH was carried out by adding a radioactive 
riboprobe specific for IFITM to intact sections of DLPFC tissue. The probe bound to IFITM 
mRNA, such that the areas of the tissue that exhibited the most radioactivity corresponded with 
the cell types that have the highest levels of IFITM mRNA. We then quantified the relative 
difference in radioactivity between individuals with schizophrenia and control subjects. We used 
two methods to quantify mRNA expression: film analysis and grain counting. For the film 
analysis, each slide of tissue processed by in situ hybridization was exposed to a sheet of film for 
a standardized length of time along with radioactive standards, and optical density measures 
were taken of the gray and white matter from the film. For the grain counting analysis, tissue 
sections were dipped in a nuclear emulsion. Over a period over 10 days, the radioactive particles 
from the bound riboprobe hit the emulsion, creating a superimposed autoradiograph of silver 
grains over the slide. To identify cell bodies, tissue sections were then counterstained for Nissl 
substance. We then examined each slide under a microscope in dark field, for the visualization 
and quantification of silver grain density which is related to the amount of IFITM mRNA 
expression over cell bodies. 
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2.4.2 Specific Procedure 
A 266–base pair fragment corresponding to bases 145-410 of the human IFITM2 gene 
(NM_006435), a homologous region in all three human IFITM variants, was PCR-amplified, and 
nucleotide sequencing confirmed 100% homology for the amplified fragment to the reported 
sequence. Sense and antisense 35S-labeled riboprobes were generated by in vitro transcription. In 
the hybridization procedure, 3 sections separated by at least 320 μm were chosen for each 
subject, and sections with the same rostral-caudal level were paired. One pair of sections from 
each subject pair was processed side by side in an in situ hybridization run. Following fixation 
with 4% paraformaldehyde in 0.1M phosphate-buffered saline, sections were hybridized with 
35S–labeled riboprobes in a standard hybridization buffer at 56°C for 16 hours. Sections were 
subsequently washed in a solution containing 50% formamide at 63°C, treated with RNase A at 
37°C, and washed in 0.1×SSC (150 mM sodium chloride, 15mM sodium citrate) at 66°C. 
Sections were then dehydrated through a graded ethanol series, air-dried, and exposed to BioMax 
MR film (Eastman Kodak, Rochester, New York) for 43 hours. Sections were then coated with 
NTB emulsion (Eastman Kodak), exposed for 10 days at 4°C, developed with D-19 developer 
(Eastman Kodak), and counterstained with cresyl violet (Volk et al. 2000;Hashimoto et al. 
2003;Morris et al. 2008). 
Levels of IFITM mRNA expression were quantified in film autoradiograms using a 
Microcomputer Imaging Device system (Imaging Research Inc, London, Ontario, Canada) 
without knowledge of diagnosis or subject number by random coding. Images of the tissue 
sections were also captured and superimposed onto the autoradiographic images to identify the 
gray matter/white matter border. Gray matter optical density was measured by drawing contours 
of the full thickness of the cortex exclusively in the zones where the cortex was cut perpendicular 
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to the pial surface. The mean (SD) total area of gray matter sampled in each subject was 76 (28) 
mm2 for control subjects and 72 (40) mm2 for subjects with schizophrenia. White matter optical 
density was determining by outlining the gray matter/white matter border and including all white 
matter on the section. The mean total areas of the sampled total white matter per subject were 
243 (113) mm2 for control subjects and 223 (99) mm2 for subjects with schizophrenia. Optical 
density is expressed as nCi/g of tissue by reference to radioactive carbon 14 standards (American 
Radiolabeled Chemicals, St Louis) exposed on the same film.   
IFITM mRNA expression was then evaluated at the cellular level using the MCID system 
coupled to a microscope equipped with a motor-driven stage. Silver grains generated by the 35S-
labeled riboprobe in emulsion-dipped sections were counted over traced outlines of blood 
vessels, identified as distinct clusters of packed cells with at least two elongated nuclei and the 
occasional presence of a lumen or branching point, in two 500 µm-wide gray matter traverses in 
each of three sections/subject. The mean (SD) number of blood vessels sampled in each subject 
was 70 (10) for control subjects and 73 (10) mm2 for subjects with schizophrenia. 
2.5 ANTIPSYCHOTIC-EXPOSED MONKEYS 
Young adult, male, long-tailed monkeys (Macacafascicularis) received oral doses of haloperidol, 
olanzapine or placebo (n=6 monkeys per group) twice daily for 17–27 months(Dorph-Petersen et 
al. 2005).One monkey from each of the three groups were euthanized together on the same day, 
and the six triads were euthanized on separate days. RNA was isolated from prefrontal cortical 
area 9, and qPCR was conducted for the same three reference genes and IFITM (Table 2) with all 
monkeys from a triad processed together on the same plate. The expression levels of the 
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reference genes (beta actin, cyclophilin A, and GAPDH) did not differ between haloperidol-
exposed, olanzapine-exposed, and placebo-exposed monkeys (F(2,10)≤1.3, p≥0.32).All animal 
studies followed the NIH Guide for the Care and Use of Laboratory Animals and were approved 
by the Institutional Animal Care and Use Committee. 
2.6 STATISTICAL ANALYSIS 
The ANCOVA model we report includes mRNA level (i.e. normalized expression level, optical 
density, or grain density) as the dependent variable, diagnostic group as the main effect, subject 
pair as a blocking factor, and postmortem interval, brain pH, RIN, and freezer storage time as 
covariates. Subject pairing may be considered an attempt to account for the parallel processing of 
tissue samples from a pair and to balance diagnostic groups for sex and age, and not a true 
statistical paired design. Therefore, a second ANCOVA model without subject pair as a blocking 
factor and including sex and age at death as covariates was also used, and both models produced 
similar results. Subsequent analyses of differences in mRNA levels between schizophrenia 
subjects grouped by predictors and indicators of disease severity, psychotropic medications, 
nicotine use, and cause of death were conducted using the unpaired ANCOVA models with 
α=.05.For the antipsychotic-exposed monkey study, an ANOVA model with mRNA level as the 
dependent variable, treatment group as the main effect, and triad as a blocking factor was 
employed. 
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3.0  RESULTS 
3.1 AIM 1: QPCR AND AUTORADIOGRAPH ANALYSIS OF IFITM MRNA  
qPCR analysis revealed that mean mRNA levels in schizophrenia subjects were markedly higher 
for IFITM1 (+72%; F(1,53)=20.0, p<.0001) and IFITM 2/3 (+116%; F(1,53)=26.8, p<.0001) relative 
to healthy comparison subjects (Figure 4). This finding is consistent with the elevation in IFITM 
mRNA levels reported in schizophrenia in the 2007 Arion et al. study, which used fourteen of the 
57 schizophrenia subjects in the present study (Arion et al. 2007). In the newly studied 43 
schizophrenia subjects alone, we also found higher mRNA levels for IFITM1 (+76%; 
F(1,39)=13.9, p=.001) and IFITM 2/3 (+118%; F(1,39)=16.6, p<.001). Since mRNA levels for 
IFITM1 and IFITM2/3 are highly correlated across all subjects (r=0.74, p<.0001) and the 
different IFITM variants have similar roles as viral restriction factors (Brass et al. 2009;Huang et 
al. 2011;Lu et al. 2011), we focused on IFITM2/3 mRNA levels for subsequent data analyses due 
to the more robust elevation seen in this variant.  
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We further validated this finding using in situ hybridization in 21 (out of 57) of the 
subject pairs that had higher IFITM mRNA expression in the schizophrenia subject by qPCR and 
had a sufficient number of available tissue sections. To our knowledge, in situ hybridization 
analysis of IFITM mRNA expression has not been previously reported in human PFC. Optical 
density analysis of film autoradiographs revealed that mean IFITM mRNA levels were higher in 
the gray matter (+110%; F(1,17)=16.0, p=.001) and white matter (+85%; F(1,17)=9.6, p=.006) in 
schizophrenia (Figure 5). Furthermore, gray matter IFITM mRNA levels quantified by in situ 
hybridization and by qPCR were correlated in the same subjects (r=.54, p=.01), which indicates 
Figure 4. Quantitative PCR analysis of IFITM mRNA levels in the prefrontal cortex in 
schizophrenia.  
mRNA levels for schizophrenia subjects relative to matched healthy comparison subjects in a 
pair are indicated by open circles. Data points to the left of the unity line indicate higher mRNA 
levels in the schizophrenia subject relative to the healthy comparison subject and vice versa. 
Mean mRNA levels (± standard deviation) in schizophrenia subjects were statistically 
significantly higher for IFITM1 (0.027 ± 0.017) and IFITM2/3 (0.078 ± 0.058) relative to 
healthy comparison subjects (IFITM1: 0.016 ± 0.005; IFITM2/3: 0.036 ± 0.011). 
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the reliability of the mRNA quantification techniques and the reproducibility of the results. 
Interestingly, pseudocolor film autoradiographs from schizophrenia subjects (Figure 5B) 
revealed small structures with intense signal that were linear, round, and/or had branch points, 
which is consistent with labeling of blood vessels. 
 
 
 
 
 
 
 
Figure 5. Autoradiograph analysis of in situ hybridization for IFITM mRNA in the 
prefrontal cortex of schizophrenia and healthy comparison subjects.  
Pseudocolored film autoradiographs of tissue sections from a matched pair of healthy 
comparison (A) and schizophrenia (B) subjects processed by in situ hybridization with an 
35S-riboprobe for IFITM mRNA are shown. Solid white line indicates the gray 
matter/white matter border. While the healthy subject has relatively low levels (colder 
colors; scale) of IFITM mRNA throughout the gray and white matter, the schizophrenia 
subject has distinct small structures with intense signal (warmer colors) that are linear, 
round, and/or have branch points, which is consistent with the anatomical appearance of 
blood vessels. Mean IFITM mRNA levels in the gray matter (C) and white matter (D) of 
prefrontal cortical area 9 for schizophrenia subjects relative to matched healthy comparison 
subjects in a pair are indicated by open circles. Data points to the left of the unity line 
indicate higher mRNA levels in the schizophrenia subject relative to the healthy 
comparison subject and vice versa. Mean IFITM mRNA levels are markedly higher in the 
gray matter (+110%) and white matter (+85%) in schizophrenia subjects. 
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3.2 AIM 2: IFITM AND DISEASE-ASSOCIATED FACTORS 
Among schizophrenia subjects, IFITM mRNA levels did not differ as a function of factors that 
predict a more severe course of illness (male sex, a diagnosis of schizophrenia rather than 
schizoaffective disorder, first-degree relative with schizophrenia, early age at illness onset [≤18 
years of age]) or measures of illness severity (suicide, no history of marriage, low socioeconomic 
status as measured by the Hollingshead Index of Social Position, living dependently at the time 
of death) (all F<.33, p>.56; Figure 6A). We also found no relationship between use of 
antipsychotic, antidepressant, benzodiazepine, or nicotine at time of death and IFITM mRNA 
levels in schizophrenia subjects (all F<1.2, p>0.28; Figure 6B). IFITM mRNA levels also did not 
differ in the PFC of monkeys chronically exposed to antipsychotics (haloperidol and olanzapine) 
or placebo (Figure 7; F(2,10)=1.3, p=.31). These data suggest that elevated IFITM mRNA levels in 
schizophrenia are not associated with disease severity and are not attributable to the effects of 
psychotropic medication.  
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Figure 6. Relationship between disease severity and psychotropic medications and IFITM 
mRNA levels in schizophrenia.  
A. Schizophrenia subjects were divided into groups based on 1) factors predictive of disease severity 
including sex, diagnosis of schizophrenia (SZ) or schizoaffective disorder (SA), family history of a 
first degree relative with schizophrenia, and age at onset of schizophrenia in years; and 2) factors 
that measure impairment in functioning including suicide as cause of death, history of marriage, 
highest achieved socioeconomic status (SES) as indicated by Hollingshead Index of Social Position, 
and living independently at time of death. Horizontal black line indicates mean IFITM mRNA level 
for each subject group. Information on family history was not available for one schizophrenia 
subject. IFITM mRNA levels did not differ as a function of any of these factors (all F<.33, p>.56). 
B. Schizophrenia subjects were also divided into groups based on use of antipsychotic, 
antidepressant, or benzodiazepine or valproic acid medications or use of nicotine at time of death. 
Information on nicotine use was not available for eight schizophrenia subjects. IFITM mRNA levels 
did not differ as a function of any of these psychoactive substances (all F<1.2, p>0.28). 
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We next sought to determine whether higher IFITM mRNA levels in schizophrenia may 
be related to infection/inflammation-related cause of death (See Appendix A). Brain tissue from 
our cohort of human subjects is acquired from autopsies conducted at the Allegheny County 
Medical Examiner's Office. Not surprisingly, the most common cause of these initially 
unexplained deaths for both schizophrenia (24/57 subjects) and healthy comparison subjects 
(43/57) is cardiopulmonary-related illness (e.g., atherosclerotic coronary vascular disease, 
cardiomyopathy, pulmonary embolism;) while only five schizophrenia and one healthy 
comparison subject had infection/inflammation-related cause of death (i.e. peritonitis, 
myocarditis, pneumonia, and anaphylaxis). (Sixteen schizophrenia subjects but no healthy 
comparison subjects died by suicide.) Only including subjects with cardiopulmonary-related 
cause of death revealed that IFITM mRNA levels were still much higher in schizophrenia 
Figure 7. IFITM mRNA levels in prefrontal area 9 of antipsychotic-exposed monkeys.  
qPCR analysis revealed no statistically significant differences in IFITM mRNA levels (mean 
± standard deviation) in monkeys chronically exposed to either olanzapine (0.0120 ± 0.0016; 
dark gray triangles) or haloperidol (0.0107 ± 0.0011; black triangles) compared to placebo 
(0.0115 ± 0.0017; light gray triangles). Mean values are shown as horizontal black bars. 
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subjects (+77%; 0.061± 0.030; F(1,59)=25.9, p<.0001) relative to comparison subjects (0.034 ± 
0.010), suggesting that higher IFITM mRNA levels in schizophrenia cannot be explained by 
infection/inflammation-related cause of death. 
 
3.3 AIM 3: CELL SPECIFICITY OF IFITM MRNA VIA GRAIN COUNTING 
As discussed above, qualitative assessment of the film autoradiographs suggested that IFITM 
expression was particular strong in cortical blood vessels. Consequently, we exposed the same 
tissue sections from the in-situ hybridization to nuclear emulsion and then developed and stained 
the sections for Nissl substance to conduct a grain counting analysis. Dense silver grain clusters 
indicating IFITM mRNA expression were present over distinct clusters of packed cells with 
elongated nuclei that often contained a lumen or branching point, and these cell clusters had an 
either linear or round orientation, consistent with longitudinal or transverse profiles of blood 
vessels, respectively (Figure 8). Grain clusters were also consistently observed over pia mater 
(not shown). In contrast, qualitative inspection of all schizophrenia and healthy comparison 
subjects revealed an absence of distinct grain clusters over neurons or glia. In schizophrenia 
subjects, the mean grain density over blood vessels was higher in schizophrenia subjects (+64%; 
F(1,17)=18.7, p<.001; Figure 8C) relative to comparison subjects and was highly correlated with 
gray matter optical density measures (r=.74, p<.0001). However, we were not able to quantify 
grain density over pia mater due to the limited presence of pia mater in the tissue sections.   
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3.4 AIM 4: IFITM MRNA LEVELS AND GABA MARKERS  
As discussed above, disturbances in PFC inhibitory neurons have been commonly reported in 
schizophrenia (Akbarian et al. 1995;Volk et al. 2000;Hashimoto et al. 2003;Glausier and Lewis 
2011). In a 2012 study of 42 of the schizophrenia subjects included in the present study, Volk et 
al reported lower mRNA levels for the GABA synthesizing enzyme GAD67, neuronal 
subpopulation markers parvalbumin and somatostatin, and the GABA neuron-specific 
Figure 8. Grain counting analysis of in situ hybridization for IFITM mRNA in the 
prefrontal cortex of schizophrenia and healthy comparison subjects.  
The tissue sections used for the autoradiograph analysis were exposed to nuclear 
emulsion, developed, and Nissl stained. A representative brightfield image (A) from the 
same tissue section shown in frame B illustrates a cluster of packed cells with elongated 
nuclei comprising a round structure with a lumen that is consistent with the transverse 
profile of a blood vessel. The darkfield image (B) reveals the accumulation of silver 
grains representing IFITM mRNA labeling over the blood vessel. Mean grain density 
per profile area (µm2) of blood vessel was also higher in schizophrenia subjects (+64%) 
relative to healthy comparison subjects (C). 
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transcription factor Lhx6 (Volk et al. 2012). Interestingly, in schizophrenia subjects, IFITM 
mRNA levels were inversely correlated with mRNA levels for GAD67 (r=-.38, p=.01), 
somatostatin (r=-.56, p<.0001), Lhx6 (r=-.42, p=.005), but did not reach significance for 
parvalbumin (r=-.24, p=.13). In contrast, in healthy subjects, IFITM mRNA levels were not 
correlated with GAD67, parvalbumin, or Lhx6 (for all, r<-.23, p>.15), but were inversely 
correlated with somatostatin (r=-.51, p=.001) (Figure 9A). Furthermore, the 2012 Volk et al 
study we also identified a "low-GABA-marker" subset of schizophrenia subjects (n=20) that had 
the most severe deficits in GAD67, parvalbumin, somatostatin, and Lhx6 mRNA levels (Volk et 
al. 2012).  Interestingly, differences in mRNA levels were found for IFITM mRNA (F(2,76)=15.6, 
p<.0001) among the low-GABA-marker schizophrenia subjects (n=20) relative to all other 
schizophrenia (n=22) and healthy (n=42) subjects (Figure 9B).  IFITM mRNA levels were even 
higher in the low-GABA-marker schizophrenia subjects relative to other schizophrenia subjects 
(+61%, p=.001) and to healthy comparison subjects (+148%, p<.0001). The finding that 
schizophrenia subjects with higher IFITM mRNA levels in endothelial cells also have greater 
disturbances in cortical GABA neurons suggests that these cell-type distinct pathological 
disturbances may be influenced by a shared upstream insult. 
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Figure 9. Relationship between IFITM mRNA levels and GABA neuron-related markers in 
schizophrenia.  
A. Quantitative PCR analysis revealed that in schizophrenia subjects (grey circles; black linear regression 
lines, n=42 subjects), IFITM mRNA levels were inversely correlated with mRNA levels for GAD67 (r=-
.38, p=.01), somatostatin (r=-.56, p<.0001), Lhx6 (r=-.42, p=.005), and almost for parvalbumin (r=-.24, 
p=.13). In contrast, in healthy subjects (open circles, dashed linear regression lines, n=42 subjects), IFITM 
mRNA levels were not correlated with GAD67, parvalbumin, or Lhx6 (for all, r<-.23, p>.15), but were 
inversely correlated with somatostatin (r=-.51, p=.001). B. IFITM mRNA levels were even higher in the 
low-GABA-marker schizophrenia subjects (dark grey circles; n=20) relative to other schizophrenia subjects 
(light grey circles; n=22) and to healthy comparison subjects (open circles; n=42). IFITM mRNA levels 
were also higher in the schizophrenia subjects not included in the low-GABA-marker subset relative to 
healthy comparison subjects. 
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4.0  CHAPTER 4: DISCUSSION 
4.1 SUMMARY OF FINDINGS 
In this study, we found marked elevations in IFITM mRNA levels in the prefrontal cortex in 
schizophrenia which is consistent with the findings of prior studies (Arion et al. 2007;Saetre et 
al. 2007) and suggests that higher IFITM mRNA levels are a common feature of schizophrenia. 
Specifically, via qPCR analysis, there was a 72% elevation for IFITM1 mRNA and a 116% 
elevation for IFITM2/3 mRNA expression suggesting elevated expression of all known isoforms 
of IFITM mRNA in the disorder.   
 Further evaluation using film autoradiographs revealed intense signal over small 
structures with features characteristic of blood vessels (i.e. linear, round, branching structures). 
Furthermore, film analysis demonstrated the absence of a detectable laminar pattern for IFITM 
mRNA labeling (data not shown) and similar levels of IFITM mRNA expression in the gray and 
white matter, which is also consistent with the presence of IFITM mRNA expression in blood 
vessels. Using a film analysis, we found a 110% elevation in optical density for IFITM mRNA 
expression in gray matter in schizophrenia and an 85% elevation in white matter.  Analysis of 
Nissl-stained, emulsion dipped tissue sections finally confirmed that IFITM mRNA is 
predominantly expressed in anatomical structures consistent with blood vessels.  Grain counting 
analysis revealed a 64% increase in grain density over gray matter blood vessels in schizophrenia 
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subjects relative to control subjects. Large, concentrated grain clusters were also visible over pia 
mater, although the lack of consistently available pia for analysis across subjects prevented 
quantitative study.  
 Interestingly, we also found that in schizophrenia subjects, IFITM mRNA levels 
quantified by qPCR were negatively correlated with the mRNA levels of GABA-related markers 
detected via the same method. Specifically, there were statistically significant, negative 
correlations between IFITM and GAD67, somatostatin, and Lhx6 mRNA, as well as a trend 
association between IFITM and parvalbumin in schizophrenia subjects. Moreover, when grouped 
as high- and low-GABA-marker expressers, the low-GABA-marker schizophrenia subjects had 
even higher levels of IFITM expression. In contrast, in control subjects, there were no 
statistically significant correlations between IFITM and GAD67, parvalbumin, or Lhx6 (although 
SST was negatively correlated). This finding suggests that the IFITM elevation and GABA-
related marker deficits may share the same upstream result. 
 
4.2  POTENTIAL CONFOUNDS 
We next sought to further establish the validity of these findings by determining whether higher 
IFITM mRNA levels were related to potential confounding factors. We found no relationship 
between psychotropic medication or nicotine use and IFITM mRNA levels at time of death in 
schizophrenia subjects. Similarly, monkeys chronically exposed to antipsychotics or placebo did 
not differ in IFITM mRNA levels.  
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 Because of IFITM’s role in immunoprotection, the elevation in postmortem IFITM 
mRNA levels in schizophrenia subjects might have been related to a late-life immune event, 
instead of a core feature of the disease. However, this is highly unlikely because the vast 
majority of control subjects and schizophrenia subjects died of cardiopulmonary events, trauma, 
or suicide. Indeed, less that 6% of the causes of deaths for the cohort in the study were related to 
infection or inflammation. Furthermore, higher IFITM mRNA levels were present in the vast 
majority of schizophrenia subjects (i.e. higher in 50 of the 57 schizophrenia subjects relative to 
matched healthy comparison subjects), suggesting that elevated IFITM mRNA in schizophrenia 
is unlikely to be explained by undetected late-life immune events that may have occurred at a 
higher frequency in schizophrenia than in comparison subjects. These data suggest that higher 
IFITM levels in schizophrenia cannot be explained by a late-life immune event, such as infection 
or inflammation. 
 A final piece of evidence for the validity of the study findings is that there was a strong 
association between the qPCR and in situ hybridization data which utilize completely different 
methods of mRNA quantification. Indeed, there was a high, positive correlation between IFITM 
mRNA levels found via qPCR and optical densities found via in situ hybridization for. This 
suggests that the finding of elevated IFITM mRNA in schizophrenia is both robust and 
reproducible across different techniques.  
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4.3 POTENTIAL UNDERLYING MECHANISMS 
The present study clearly illustrates that there is an elevation in IFITM mRNA levels in the 
DLPFC of individuals with schizophrenia that is especially profound in gray matter blood 
vessels. Recent studies have found that IFITM proteins act to restrict viral replication early in the 
viral life cycle by preventing the virus from fusing with the cell membrane (Feeley et al. 
2011;Huang et al. 2011). This early restriction allows IFITM to have antiviral effects against a 
wide range of viruses that involve viral fusion, including influenza, filoviruses, flaviviruses, and 
coronaviruses. IFITM isoforms1-3, which were the variants studied here, are ubiquitous in the 
body and are present at basal levels in cells, even in the absence of interferon induction (Tanaka 
et al. 2005). This may help explain why there were detectable levels of IFITM mRNA in all 
subjects, including controls, even though the degree of expression was different between groups. 
Given its broad-spectrum antiviral function and its potential role in immune cell signaling, 
IFITM overexpression in schizophrenia may be an indicator of a state of heightened immune 
activity(Diamond and Farzan 2013). From this limited knowledge of IFITM function, we now 
discuss three pathogenetic mechanisms that may contribute to overexpression of IFITM mRNA 
in cortical blood vessels in schizophrenia. Namely, the elevation in IFITM mRNA levels could 
be involved in or a consequence of a(n): 
1. Early immune insult such as maternal immune activation 
2. Chronic state of neuroinflammation 
3. Disruption in the microvasculature of the blood-brain barrier 
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4.3.1 Maternal Immune Activation 
As discussed above, maternal immune activation (MIA) has been reported to increase the risk of 
schizophrenia in offspring (Brown and Derkits 2010). For example, the presence of antigens to 
influenza or antibodies to toxoplasmosis in maternal serum during pregnancy not only predicts 
development of schizophrenia in the offspring, but is actually associated with worse performance 
on cognitive tasks even among schizophrenia patients (Brown et al. 2005). Furthermore, in 
studies that injected pregnant mice with immune-activating agents such as lipopolysaccharide  or 
poly I:C, offspring have been shown to exhibit deficits in working memory (Oskvig et al. 
2012;Meyer et al. 2008;Meyer et al. 2006;Dickerson et al. 2010). MIA in mice has also been 
shown to cause reductions in cortical parvalbumin immunoreactivity and abnormalities in PFC 
neural firing patterns associated with parvalbumin neurons that subserve working memory 
function in offspring (Dickerson et al. 2010;Meyer et al. 2008). Taken together, these findings 
indicate that MIA may be an integral part of the development of the PFC dysfunction 
characteristic of the cognitive deficits in schizophrenia. 
Because increased schizophrenia risk has been associated with MIA due to viral (Brown 
et al. 2000), parasitic (Brown et al. 2005), or bacterial (Sorensen et al. 2009) pathogens, the 
phenomenon does not appear to be pathogen-specific. In other words, the increased risk is not 
directly caused by any given pathogen in-utero, but rather by a generalized immunological 
mechanism initiated by the mother’s immune system. A prominent theory in the literature is that 
these elevations in fetal cytokines, which at normal levels facilitate a number of crucial 
neurodevelopmental processes such as neural induction, neurogenesis, neuron differentiation, 
and neural migration (Deverman and Patterson 2009), is a primary mediator of the disruptions in 
neurodevelopment that ultimately put the fetus at risk for developing schizophrenia later in life 
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(Gilmore and Jarskog 1997;Patterson 2009). Consistent with this theory, studies in which 
cytokines were injected directly into newborn rodent pups found that the cytokines disrupted 
neurodevelopment and led to cognitive and behavioral deficits similar to those seen in 
schizophrenia (Nawa and Takei 2006).  
 An important implication of the cytokine-mediated offset in neurodevelopment is that the 
MIA-related elevation in cytokines early in life may persist into adulthood as result of 
permanently altered gene regulation. Indeed, maternal immune activation can induce long-lasting 
epigenetic changes at gene promoters in offspring (Tang et al. 2013), although it is unclear if 
MIA specifically induces epigenetic changes at the promoters for IFITM or GABA-related 
markers. Furthermore, MIA has been shown to lower mRNA levels for GAD67 and vesicular 
GABA transporter in the prefrontal cortex of adult mice (Richetto et al. 2013), similar to that 
seen in schizophrenia (Volk et al. 2012;Hoftman et al. 2013). MIA also raises levels of pro-
inflammatory cytokines in splenocytes of adult rats (Basta-Kaim et al. 2012), including cytokines 
(e.g, IL-6) known to induce IFITM expression (Bailey et al. 2012). In addition, mice that were 
exposed to poly:IC early in development (but after birth) exhibited higher IFITM3 expression in 
astrocytes that was shown to contribute to impairment in neurite development via neuron cell 
culture. This developmental impairment was not seen in neuron cell cultures with IFITM3 
knockout astrocytes, suggesting that IFITM may play a mechanistic role in the immune-related 
neurodevelopmental offset hypothesized to be involved in schizophrenia (Ibi et al. 2013). 
Notably, however, IFITM mRNA elevations in astrocytes were not found in the present study.  
Taken together, these findings indicate that, while further proof-of-principle testing is 
needed, an early immune insult such as MIA may contribute to long-lasting elevations in IFITM 
mRNA levels and deficits in GABA-related mRNAs in adult brain through multiple mechanisms 
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of disrupting early fetal development by elevating cytokine levels in fetal brain (Meyer et al. 
2006) and through enduring epigenetic modifications at gene promoter regions (Tang et al. 
2013). One way to further investigate this hypothesis would be create a mouse model of MIA via 
poly I:C injection and then measure prefrontal IFITM mRNA expression in the offspring with 
the prediction that there will be higher IFITM mRNA levels in the offspring whose mothers were 
exposed to Poly I:C than those who were not.  
 
4.3.2 Chronic Neuroinflammation 
Regardless of its origin, abnormal immune activity is a remarkably conserved finding in 
schizophrenia. Studies examining serum and cerebrospinal fluid have found consistently 
abnormal cytokine levels in schizophrenia, although there are many contradictory findings in 
terms of which specific cytokines are over- or underexpressed in the disease (Di Nicola et al. 
2012;Drzyzga et al. 2006;Miller et al. 2011;Potvin et al. 2008). Importantly, however, cytokines 
involved in inflammatory processes (e.g, IL-6 and IL-1β) are among the most commonly found 
to be abnormal, suggesting that there is an inflammatory component to schizophrenia. Indeed, 
PET imaging has revealed that schizophrenia patients injected with a radioactive tag for 
neuroinflammation (PK-11195) exhibit higher binding than do healthy comparisons (Doorduin et 
al. 2009;van Berckel et al. 2008). Furthermore, microglia, which heavily contribute to 
inflammatory processes in the brain, may be present in higher density in area 9 in schizophrenia 
(Radewicz et al. 2000). More support for the presence of a neuroinflammatory component to the 
disorder has come from genome-wide association studies (GWAS), which have found that 
schizophrenia is highly associated with gene variants in the MHC region (Ripke et al. 2011;Irish 
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Schizophrenia Genomics Consortium and the Wellcome Trust Case Control Consortium 2 ;Jia et 
al. 2010). These gene variants tend to correspond to players in inflammatory signaling pathways, 
such as TGFβ and TNF (Jia et al. 2010). 
Interestingly, the 2012 Fillman et al study found both elevated pro-inflammatory 
cytokines (IL-6, IL-1β, IL-8) and deficient GABA markers (somatostatin, parvalbumin, GAD67) 
in a subset of schizophrenia subjects. In the same cohort, the study also found higher mRNA 
expression of IFITM1 mRNA in the DLPFC in schizophrenia. IFITM proteins have be shown to 
be associated with a variety of inflammatory diseases, including ulcerative colitis and 
inflammatory bowel disease, so it is plausible for IFITM to be involved in inflammatory 
processes in the brain (Seo et al. 2010;Wu et al. 2007). Indeed, the 2007 Arion et al study 
demonstrated a strong association between IFITM and immune-related transcripts such as 
SERPINA3, which has been linked to inflammatory processes (Horvath et al. 2005;Arion et al. 
2007).  Moreover, elevated SERPINA3, HLA-A, and IFITM mRNA expression were found to 
co-occur in the PFC in schizophrenia in another microarray study (Saetre et al. 2007). These 
findings are especially interesting in light of the present study’s demonstrations that GABA 
marker mRNA deficits are correlated with IFITM mRNA elevation and that the IFITM elevation 
is particularly pronounced in blood vessels, which are intricately involved in neuroinflammation. 
Taken together, these findings suggest that neuroinflammation may be related to both GABA 
circuitry dysfunction (e.g. perhaps parvalbumin neurons are particularly susceptible to the 
deleterious effects of chronic neuroinflammation) and IFITM mRNA overexpression in the 
DLPFC in schizophrenia, although they do not elucidate the directionality the relationships. 
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4.3.3 Blood Brain Barrier Abnormality 
Because the present study shows that IFITM mRNA is present in high levels specifically in 
DLPFC blood vessels, it is plausible that there is disrupted microvasculature within the region. If 
so, then elevated IFITM mRNA levels in schizophrenia in endothelial cells could be indicative of 
a dysfunctional blood-brain barrier (BBB) in the disorder.  
Indeed, CSF albumin protein levels, which are a broad indicator of BBB function and 
permeability, are elevated in schizophrenia (Kirch et al. 1992;Kirch et al. 1985;Muller et al. 
1999). Additionally, a study looking at mRNA expression of vascular endothelial growth factor 
(VEGF), an angiogenetic factor involved in the regulation of cerebral blood flow, found 
markedly decreased mRNA levels in the DLPFC in schizophrenia (Fulzele and Pillai 2009).  
The status of BBB function can also be assessed by investigating the function of 
astrocytes, which are heavily involved in the development and maintenance of the BBB. 
Specifically, astrocytic endfeet envelop the outer surface of the CNS blood vessel endothelium, 
allowing for induction of new vessels and vessel branches (Janzer and Raff 1987). Additionally, 
the anatomical proximity of astrocytes and endothelia allows for both short- and long-term 
modulation of the permeability of the tight junctions that form the BBB (Abbott 2002). 
Therefore, if markers of astrocyte function are shown to be abnormal in schizophrenia, then BBB 
function can also be assumed to be abnormal. Indeed, a number of studies have investigated glial 
acidic fibrillary protein (GFAP), which is involved in astrocyte cytoskeleton integrity (Harrison 
and Mobley 1992), and overall glial cell density. In both cases, there has not been an overall 
difference in schizophrenia, although both GFAP expression and glial cell density might be 
down in cortical layer 5 and there may be lower GFAP expression in the anterior cingulate cortex 
(Cotter et al. 2001;Rajkowksa et al. 2002).  
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Furthermore, in schizophrenia it has been well-established that S100B, a calcium-binding 
protein that is integrally important to and predominantly expressed by astrocytes, is elevated in 
the serum of individuals with schizophrenia (Rothermundt et al. 2009). There is also evidence 
that S100B is elevated in both the CSF and post-mortem cortical brain tissue, especially in the 
DLPFC (Rothermundt et al. 2009;Steiner et al. 2006;Steiner et al. 2008). Interestingly, there are 
positive associations between elevated S100B serum levels and negative symptom severity in 
schizophrenia (Rothermundt et al. 2004;Pedersen et al. 2008). S100B has also been implicated in 
the regulation of inflammatory processes and other immune functions (Donato 2003), so elevated 
S100B in schizophrenia lends support to the hypothesis that dysfunctional BBB is involved in 
the immunological abnormalities found in the disorder. In fact, it has been proposed that the 
cerebral microvasculature is the primary site of neuroinflammation in the disease (Hanson and 
Gottesman 2005). One way to test the status of IFITM in BBB dysfunction in schizophrenia 
would be to investigate the expression of BBB-related markers such as S100B and VEGF in the 
same schizophrenia subjects who have elevated IFITM mRNA levels with the prediction that 
alterations in these BBB-related markers are greatest in the same schizophrenia subjects. 
Taken together, these findings suggest that the agents involved in BBB formation and 
maintenance are distinctly abnormal. Because neurodevelopment and cerebral microvasculature 
function are closely interdependent (Saunders et al. 2008), abnormalities in the cells that form 
the BBB, such as increased IFITM expression in the DLPFC, may be related to the abnormalities 
in neurodevelopment that ultimately result in core pathologic findings seen in schizophrenia, 
such as GABA circuitry dysfunction.  
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4.3.4 An Integrative Interpretation 
The three interpretations discussed here (MIA, chronic neuroinflammation, and BBB disruption) 
are by no means mutually exclusive, and in fact may all be involved in the blood vessel-specific 
overexpression of DLPFC IFITM mRNA found in schizophrenia in the present study. For 
example, maternal immune activation may serve as an etiologic source which, when combined 
with genetic predisposition and other environmental factors, results in chronic elevation of 
cytokines that cause persistent neuroinflammation. This elevation in cytokines and resulting 
neuroinflammation may contribute directly to GABA circuitry dysfunction and ultimately to the 
cognitive deficits seen in schizophrenia. At the same time, the inflammation may also disrupt the 
BBB such that a recursive increase in inflammation occurs, further disrupting normal 
neurodevelopment (Hanson and Gottesman 2005). The association of IFITM overexpression 
with blood vessels and markers of both GABA circuitry dysfunction and neuroinflammation in 
the DLPFC suggests that IFITM plays an integral role in these phenomena.  
4.4 CLINICAL IMPLICATIONS 
If the GABA-marker deficits and IFITM overexpression in the DLPFC are downstream 
consequences of MIA, then preventative prenatal care may reduce the risk of schizophrenia 
development in at-risk offspring. For example, prevention of the maternal infection in the first 
place (via vaccinations or personal health practice) or rapid treatment of maternal infection if it 
occurs may help mitigate the deleterious effects of MIA (Brown and Derkits 2010).  
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 Independent of its relationship to MIA, the chronic state of neuroinflammation seen in 
schizophrenia could be targeted by immune-modulating agents like non-steroidal anti-
inflammatory drugs (NSAIDs). By reducing neuroinflammation, such drugs could alleviate some 
of the circuitry dysfunction seen in the disorder. Indeed, the COX-2 inhibitor celecoxib has been 
shown to improve both positive and negative symptoms, as measured by the Positive and 
Negative Symptom Scale (PANSS), more than antipsychotic treatment alone (Akhondzadeh et 
al. 2007;Muller et al. 2010).  
 A third clinical approach would be to target the pathway leading to IFITM synthesis 
directly, thereby preventing its overexpression. IFITM expression is a downstream result of 
INFα/β receptor binding and subsequent activation of Janus kinase (JAK) and signal transducer 
and activator of transcription (STAT) proteins. The JAK-STAT signaling pathway results in the 
translocation of a transcription factor complex into the nucleus of the cell, where IFITM mRNA 
is transcribed. Ruxolitinib is an example of a drug that interferes with this process by inhibiting 
JAK. Although FDA approved for the treatment of myelofibrosis, Ruxolitinib could a potentially 
lower IFITM expression (Deisseroth et al. 2012). In fact, the JAK-STAT pathway is involved in 
the signal transduction for broad range of pro-inflammatory cytokines, so inhibition the pathway 
could conceivably attenuate the effects of the cytokine overexpression seen in the disorder (Pesu 
et al. 2008).  
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APPENDIX 
DEMOGRAPHIC, POSTMORTEM, AND CLINICAL CHARACTERISTICS OF 
HUMAN SUBJECTS USED IN THIS STUDY 
Table 1. Control subject characteristics 
Pair Case Sex/ Race Age PMI
a 
Storage 
Time 
qPCRb 
Storage 
Time In 
Situ 
RIN pH Cause of Death 
1 592 M/B 41 22.1 182  9.0 6.7 ASCVD 
2 567 F/W 46 15.0 186  8.9 6.7 
Mitral valve 
prolapse 
3 516 M/B 20 14.0 194  8.4 6.9 
Homicide by gun 
shot 
4 630 M/W 65 21.2 176  9.0 7.0 ASCVD 
5 604 M/W 39 19.3 180  8.6 7.1 
Hypoplastic 
coronary artery 
6 546 F/W 37 23.5 190  8.6 6.7 ASCVD 
7 551 M/W 61 16.4 189  8.3 6.6 Cardiac tamponade 
8 685 M/W 56 14.5 169  8.1 6.6 
Hypoplastic 
coronary artery 
9 681 M/W 51 11.6 170  8.9 7.2 
Hypertrophic 
cardio-myopathy 
10 806 M/W 57 24.0 149  7.8 6.9 
Pulmonary 
embolism 
11 822 M/B 28 25.3 146  8.5 7.0 ASCVD 
12 727 M/B 19 7.0 163  9.2 7.2 Trauma 
13 871 M/W 28 16.5 135  8.5 7.1 Trauma 
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Table 1. Control subject characteristics 
Pair Case Sex/ Race Age PMI
a 
Storage 
Time 
qPCRb 
Storage 
Time In 
Situ 
RIN pH Cause of Death 
14 575 F/B 55 11.3 185  9.6 6.8 ASCVD 
15 700 M/W 42 26.1 167  8.7 7.0 ASCVD 
16 988 M/W 82 22.5 114  8.4 6.2 Trauma 
17 686 F/W 52 22.6 169  8.5 7.0 ASCVD 
18 634 M/W 52 16.2 176  8.5 7.0 ASCVD 
19 852 M/W 54 8.0 139  9.1 6.8 Cardiac tamponade 
20 987 F/W 65 21.5 114  9.1 6.8 ASCVD 
21 818 F/W 67 24.0 147  8.4 7.1 
Anaphylactic 
reaction 
22 857 M/W 48 16.6 138  8.9 6.7 ASCVD 
23 739 M/W 40 15.8 162  8.4 6.9 ASCVD 
24 1047 M/W 43 13.8 105 116 9.0 6.6 ASCVD 
25 1086 M/W 51 24.2 99 110 8.1 6.8 ASCVD 
26 1092 F/B 40 16.6 99  8.0 6.8 
Mitral Valve 
Prolapse 
27 10005 M/W 42 23.5 86 97 7.4 6.7 Trauma 
28 1336 M/W 65 18.4 64 75 8.0 6.8 Cardiac Tamponade 
29 1122 M/W 55 15.4 95 106 7.9 6.7 Cardiac Tamponade 
30 1284 M/W 55 6.4 74  8.7 6.8 ASCVD 
31 1191 M/B 59 19.4 88 99 8.4 6.2 ASCVD 
32 970 M/W 42 25.9 117  7.2 6.4 ASCVD 
33 10003 M/W 49 21.2 88  8.4 6.5 Trauma 
34 1247 F/W 58 22.7 80 91 8.4 6.4 ASCVD 
35 1324 M/W 43 22.3 67 78 7.3 7 Aortic Dissection 
36 1099 F/W 24 9.1 98 109 8.6 6.5 Cardiomyopathy 
37 1307 M/B 32 4.8 70  7.6 6.7 ASCVD 
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Table 1. Control subject characteristics 
Pair Case Sex/ Race Age PMI
a 
Storage 
Time 
qPCRb 
Storage 
Time In 
Situ 
RIN pH Cause of Death 
38 1391 F/W 51 7.8 56  7.1 6.6 ASCVD 
39 1282 F/W 39 24.5 75  7.5 6.8 ASCVD 
40 1159 M/W 51 16.7 92 103 7.6 6.5 ASCVD 
41 1326 M/W 58 16.4 66  8.0 6.7 ASCVD 
42 902 M/W 60 23.6 131 142 7.7 6.7 ASCVD 
43 1374 M/W 43 21.7 64 69 7.2 6.6 ASCVD 
44 1555 M/W 17 15.1 29  7.9 6.9 
Blunt force trauma 
to head, thorax, 
abdomen 
45 1268 M/B 49 19.9 82 87 7.9 7.1 ASCVD 
46 1466 F/B 64 20.0 47 52 8.8 6.7 Blunt force trauma to trunk 
47 1518 M/W 50 20.7 36 41 7.7 6.4 ASCVD 
48 1386 M/W 46 21.2 61  8.3 6.7 ASCVD 
49 1472 M/W 61 23.8 46 51 8.0 6.5 Pulmonary infarction 
50 1026 M/W 59 20.0 113 118 7.4 6.3 ASCVD 
51 694 M/W 38 20.7 174 179 7.7 7.0 Subarachnoid hemorrhage 
52 1350 M/W 21 24.2 67  7.3 6.4 Trauma 
53 1201 F/W 52 16.4 92 97 8.1 6.2 ASCVD 
54 1524 M/W 66 9.4 34  8.1 6.4 
Small intestinal 
ischemic infarction 
55 1270 F/W 73 19.7 81 86 7.7 6.7 Trauma 
56 1372 M/W 37 20.5 65  9.0 6.6 Asphyxiation 
57 1543 F/W 45 17.9 31 36 7.4 6.8 Subarachnoid hemorrhage 
  Mean 48.1 18.2 112.5 92.5 8.2 6.7  
  SD 13.9 5.4 49.9 33.7 0.6 0.3  
a PMI, postmortem interval (hours); b Storage time (months) at -80C; Other abbreviations: ASCVD, 
arteriosclerotic cardiovascular disease; RIN, RNA integrity number 
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Table 2a. Schizophrenia subject characteristics (Part 1) 
Pair Case DSM IV diagnosis Sex/  Race Age PMI
a 
Storage 
Time 
qPCRb 
Storage 
Time In 
Situ 
RIN pH Cause of Death 
1 533 Chronic undifferentiated schizophrenia M/W 40 29.1 192  8.4 6.8 
Accidental 
Asphyxiation 
2 537 Schizoaffective disorder F/W 37 14.5 191  8.6 6.7 
Suicide by 
hanging 
3 547 Schizoaffective disorder M/B 27 16.5 190  7.4 7.0 Heat Stroke 
4 566 Chronic undifferentiated schizophrenia; AAR M/W 63 18.3 187  8.0 6.8 ASCVD 
5 581 
Chronic paranoid 
schizophrenia; ADC; 
OAC 
M/W 46 28.1 184  7.9 7.2 
Accidental 
combined drug 
overdose 
6 587 Chronic undifferentiated schizophrenia; AAR F/B 38 17.8 183  9.0 7.0 
Myocardial 
hypertrophy 
7 625 Chronic disorganized schizophrenia; AAC M/B 49 23.5 177  7.6 7.3 ASCVD 
8 622 Chronic undifferentiated schizophrenia M/W 58 18.9 177  7.4 6.8 
Right MCA 
infarction 
9 640 Chronic paranoid schizophrenia M/W 49 5.2 175  8.4 6.9 
Pulmonary 
embolism 
10 665 Chronic paranoid schizophrenia; ADC M/B 59 28.1 173  9.2 6.9 
Intestinal 
hemorrhage 
11 787 Schizoaffective disorder; ODC M/B 27 19.2 152  8.4 6.7 
Suicide by gun 
shot 
12 829 Schizoaffective disorder; ADC; OAR M/W 25 5.0 144  9.3 6.8 
Suicide by 
salicylate 
overdose 
13 878 Disorganized schizophrenia; ADC M/W 33 10.8 135  8.9 6.7 
Myocardial 
fibrosis 
14 517 Disorganized schizophrenia; ADC F/W 48 3.7 194  9.3 6.7 
Intracerebral 
hemorrhage 
15 539 Schizoaffective disorder; ADR M/W 50 40.5 191  8.1 7.1 
Suicide by 
combined drug 
overdose 
16 621 Chronic undifferentiated schizophrenia M/W 83 16.0 178  8.7 7.3 
Accidental 
asphyxiation 
17 656 Schizoaffective disorder; ADC F/B 47 20.1 174  9.2 7.3 
Suicide by gun 
shot 
18 722 
Chronic undifferentiated 
schizophrenia; ODR; 
OAR 
M/B 45 9.1 164  9.2 6.7 Upper GI bleeding 
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Table 2a. Schizophrenia subject characteristics (Part 1) 
Pair Case DSM IV diagnosis Sex/  Race Age PMI
a 
Storage 
Time 
qPCRb 
Storage 
Time In 
Situ 
RIN pH Cause of Death 
19 781 Schizoaffective disorder; ADR M/B 52 8.0 154  7.7 6.7 Peritonitis 
20 802 Schizoaffective disorder; ADC; ODR F/W 63 29.0 150  9.2 6.4 
Right ventricular 
dysplasia 
21 917 Chronic undifferentiated schizophrenia F/W 71 23.8 127  7.0 6.8 ASCVD 
22 930 
Disorganized 
schizophrenia; ADR; 
OAR 
M/W 47 15.3 124  8.2 6.2 ASCVD 
23 933 Disorganized schizophrenia M/W 44 8.3 123  8.1 5.9 Myocarditis 
24 1209 Schizoaffective disorder M/W 35 9.1 86 97 8.7 6.5 
Suicide by 
diphenhydramine 
overdose 
25 10025 Disorganized schizophrenia; OAR M/B 52 27.1 78 89 7.8 6.7 ASCVD 
26 1178 Schizoaffective disorder F/B 37 18.9 90  8.4 6.1 
Pulmonary 
embolism 
27 1256 Undifferentiated schizophrenia M/W 34 27.4 78 89 7.9 6.4 
Suicide by 
hanging 
28 1173 Disorganized schizophrenia; ADR M/W 62 22.9 90 101 7.7 6.4 ASCVD 
29 1105 Schizoaffective disorder M/W 53 7.9 97 108 8.9 6.2 ASCVD 
30 1188 
Undifferentiated 
schizophrenia; AAR; 
OAR 
M/W 58 7.7 89  8.4 6.2 ASCVD 
31 1263 Undifferentiated schizophrenia; ADR M/W 62 22.7 78 89 8.5 7.1 
Accidental 
asphyxiation 
32 1222 Undifferentiated schizophrenia; AAC M/W 32 30.8 84  7.5 6.4 
Suicide by 
combined drug 
overdose 
33 1088 
Undifferentiated 
schizophrenia; ADC; 
OAC 
M/W 49 21.5 99  8.1 6.5 
Accidental 
combined drug 
overdose 
34 1240 Undifferentiated schizophrenia; ADR F/B 50 22.9 81 92 7.7 6.3 ASCVD 
35 10020 Paranoid schizophrenia; AAC; OAC M/W 38 28.8 80 91 7.4 6.6 
Suicide by 
salicylate 
overdose 
36 10023 Disorganized schizophrenia F/B 25 20.1 79 90 7.4 6.7 
Suicide by 
drowning 
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Table 2a. Schizophrenia subject characteristics (Part 1) 
Pair Case DSM IV diagnosis Sex/  Race Age PMI
a 
Storage 
Time 
qPCRb 
Storage 
Time In 
Situ 
RIN pH Cause of Death 
37 10024 Paranoid schizophrenia M/B 37 6.0 79  7.5 6.1 ASCVD 
38 1189 Schizoaffective disorder; AAR F/W 47 14.4 89  8.3 6.4 
Suicide by 
combined drug 
overdose 
39 1211 Schizoaffective disorder F/W 41 20.1 86  7.8 6.3 
Sudden 
unexplained death 
40 1296 Undifferentiated schizophrenia M/W 48 7.8 72 83 7.3 6.5 Pneumonia 
41 1314 Undifferentiated schizophrenia M/W 50 11.0 69  7.2 6.2 ASCVD 
42 1361 Schizoaffective disorder; ODC M/W 63 23.2 62 73 7.7 6.4 Cardiomyopathy 
43 904 Schizoaffective disorder M/W 33 28.0 136 141 7.1 6.2 Broncho-pneumonia 
44 1649 Undifferentiated schizophrenia M/B 17 21.8 15  8.1 6.9 
Suicide by 
hanging 
45 1230 Undifferentiated schizophrenia M/W 50 16.9 87 92 8.2 6.6 
Suicide by 
doxepin overdose 
46 1341 Schizoaffective disorder; ODC F/W 44 24.5 68 73 8.8 6.6 Trauma 
47 1367 Schizoaffective disorder; ADC; ODR M/W 47 28.9 66 71 7.2 6.6 
Combined drug 
overdose 
48 1420 Schizoaffective disorder; AAR; ODC; OAR M/W 47 23.4 54  8.2 6.7 Suicide by jump 
49 1453 Paranoid schizophrenia; ADR M/W 62 11.1 49 54 8.2 6.4 Trauma 
50 1454 Paranoid schizophrenia; AAR; ODC M/W 59 24.1 48 53 7.6 6.1 Trauma 
51 1455 Paranoid schizophrenia; AAR; OAC M/W 42 8.2 48 53 7.7 6.2 Peritonitis 
52 1474 Schizoaffective disorder; ADR M/W 37 39.9 46  7.0 6.7 
Suicide by 
hanging 
53 1506 Schizoaffective disorder; ADC F/W 47 14.1 40 45 7.5 6.6 
Combined drug 
overdose 
54 1542 Paranoid schizophrenia M/W 65 17.4 31  7.8 6.7 
Combined drug 
overdose 
55 1579 Schizoaffective disorder; ADR; ODC F/W 69 16.1 25 30 7.7 6.7 ASCVD 
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Table 2a. Schizophrenia subject characteristics (Part 1) 
Pair Case DSM IV diagnosis Sex/  Race Age PMI
a 
Storage 
Time 
qPCRb 
Storage 
Time In 
Situ 
RIN pH Cause of Death 
56 1581 Paranoid schizophrenia; ODC; OAC M/W 32 18.4 24  9.0 6.8 ASCVD 
57 10026 Undifferentiated schizophrenia F/W 46 23.8 83 88 7.6 6.6 
Suicide by 
thermal injuries 
   Mean 46.9 18.9 109.2 81.1 8.1 6.6  
   SD 12.9 8.5 53.7 24.7 0.6 0.3  
a PMI, postmortem interval (hours); b Storage time (months) at -80C;Other abbreviations: ASCVD, arteriosclerotic 
cardiovascular disease; MCA, middle cerebral artery; ADC, alcohol dependence, current at time of death; ADR, alcohol 
dependence, in remission at time of death; AAC, alcohol abuse, current at time of death; AAR, alcohol abuse, in remission 
at time of death; ODC, other substance dependence, current at time of death; ODR, other substance dependence, in 
remission at time of death; OAC, other substance abuse, current at time of death; OAR, other substance abuse, in remission 
at time of death; U, unknown. 
 
 
 
Table 2b. Schizophrenia subject characteristics (Part 2) 
Pair Case 
History of 
Cannabis 
Use 
APD 
ATOD 
APD 
ATOD 
BDZ/ 
VPA 
ATOD 
Family 
Historyc 
Age at 
Onset 
of 
Illness 
History of 
Marriage 
Hollingshead 
Two Factor 
ISP 
Independent 
Living 
ATOD 
1 533 None Y N N N 25 N 20 N 
2 537 None N N N N 29 Y 20 Y 
3 547 None Y Y Y N 18 N 17 N 
4 566 None Y Y Y N 43 Y 16 N 
5 581 Use Y N Y Y 16 Y 19 Y 
6 587 Use Y N Y N 18 N 17 N 
7 625 None Y Y N Y 35 Y 34 N 
8 622 None N N N N 42 N 27 N 
9 640 None Y Y N N 21 N 63 N 
10 665 None Y Y N Y 27 N 16 Y 
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Table 2b. Schizophrenia subject characteristics (Part 2) 
Pair Case 
History of 
Cannabis 
Use 
APD 
ATOD 
APD 
ATOD 
BDZ/ 
VPA 
ATOD 
Family 
Historyc 
Age at 
Onset 
of 
Illness 
History of 
Marriage 
Hollingshead 
Two Factor 
ISP 
Independent 
Living 
ATOD 
11 787 Dependent Y N N N 24 N 30 N 
12 829 Abuse in remission N N Y Y 20 N 22 N 
13 878 Use Y Y Y N 16 N 57 N 
14 517 None Y N N N 28 Y 53 N 
15 539 None Y Y Y N 19 Y 45 Y 
16 621 None N N N Y 28 N 8 N 
17 656 None Y N N Y 17 N 19 Y 
18 722 Use Y N N N 26 N 24 N 
19 781 None Y Y N N 37 Y 24 N 
20 802 None Y N Y N 20 N 42 Y 
21 917 None Y N N Y 24 Y 19 N 
22 930 Abuse Y N Y N 19 N 17 N 
23 933 None Y Y Y N 22 N 27 N 
24 1209 None Y N N N 21 Y 35 Y 
25 10025 Abuse in remission N N N N 22 N 27 N 
26 1178 None Y N Y N 26 N 40 N 
27 1256 None Y N N N 28 N 36 N 
28 1173 None Y N N N 29 Y 16 Y 
29 1105 None Y N N N 48 N 24 N 
30 1188 Abuse in remission Y N N Y 25 N 45 N 
31 1263 Use Y Y N N 21 N 11 N 
32 1222 Use Y Y N N 16 N 14 Y 
33 1088 Abuse Y Y N N 25 Y 45 N 
34 1240 None Y N N N 25 N 32 N 
35 10020 None Y Y Y N 18 N 27 N 
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Table 2b. Schizophrenia subject characteristics (Part 2) 
Pair Case 
History of 
Cannabis 
Use 
APD 
ATOD 
APD 
ATOD 
BDZ/ 
VPA 
ATOD 
Family 
Historyc 
Age at 
Onset 
of 
Illness 
History of 
Marriage 
Hollingshead 
Two Factor 
ISP 
Independent 
Living 
ATOD 
36 10023 None Y N Y Y 15 N 17 Y 
37 10024 None N N N N 20 Y 27 N 
38 1189 None Y Y Y N 43 N 66 Y 
39 1211 Use Y Y N N 29 Y 30 N 
40 1296 None Y Y N N 13 N 14 N 
41 1314 None Y Y N N 17 N 19 N 
42 1361 Use Y N Y N 16 N 17 N 
43 904  Y N Y N 25 N 30 N 
44 1649  Y Y N Y 15 N 11 N 
45 1230  Y Y N N 22 N 30 N 
46 1341  Y N Y U 14 N 11 N 
47 1367  N N N N 23 Y 50 Y 
48 1420  Y Y N N 18 N 30 N 
49 1453  N N Y N 30 N 19 N 
50 1454  Y Y N N 26 Y 32 Y 
51 1455  Y N Y N 23 Y 14 Y 
52 1474  N N N N 35 Y 35 Y 
53 1506  Y Y N N 18 Y 42 Y 
54 1542  Y N Y N 25 N 25 N 
55 1579  Y N Y N 25 Y 32 Y 
56 1581  Y Y N N 29 N 37 N 
57 10026  Y Y N N 22 Y 30 N 
c First degree relative with schizophrenia; Abbreviations: ATOD, at time of death; APD, antipsychotic drug; ADD, 
antidepressant drug; BDZ, benzodiazepine; VPA, valproic acid; ISP, index of social position; Y, yes; N, no. 
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